Clifton E. Barry

This paper identifies thienothiazolocarboxamides as rapidly cidal antituberculosis agents that cause thiol collapse in Mycobacterium tuberculosis through EthA-mediated activation.

This paper identifies DDU384, a new compound with potent in vivo efficacy against tuberculosis in murine models, showing potential to improve current treatment options.

The paper shows in vitro models of tuberculosis lesions predict treatment responses in marmosets better than conventional methods.

The paper identifies on-treatment biomarkers in TB patients by integrating immunomonitoring assays with PET/CT scans, showing significant cytokine changes and machine learning-based biomarkers for treatment response.

The paper identifies and evaluates dibasic piperidines as novel cell wall inhibitors against Mycobacterium tuberculosis, showing activity across multiple media and differential sensitivity in resistant strains.

This paper introduces Transcript-Capture Seq to enrich bacterial mRNA from host samples, enabling analysis of the complete Mtb transcriptome in clinical samples and revealing gene expression patterns associated with in vivo bacterial activity.

Rabbit lesion microdissection and pharmacokinetic modeling show bedaquiline takes months to reach deep caseum and years to clear, while TBAJ-587 and TBAJ-876 shorten these windows.

The paper identifies sphagnum-associated fungi that produce antitubercular agents inducing thiol stress in Mycobacterium tuberculosis.